ARTICLE · 10 NOVEMBER 2026
Biotech IPOs are experiencing a selective resurgence as investors diversify away from AI-heavy portfolios, with specialist and crossover capital returning to biopharma companies that demonstrate compelling clinical data and defensible intellectual property. Active pharmaceutical M&A provides crucial strategic alternatives beyond public offerings, while late-stage private financing rounds in obesity, oncology, RNA therapeutics, and other specialized areas create pathways for companies to build runway and cli
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
